$60 million to be spent on DTC ads for Sepracor sleep drug

Sepracor will spend an estimated $60 million to advertise its new insomnia drug Lunesta directly to consumers, according to a Wall Street Journal report. The drug was approved by the FDA Wednesday.
Handling the DTC account for Lunesta is McCann-Erickson, with professional work done by Torre Lazur McCann Healthcare.
Lunesta was formerly known as Estorra. Its name was changed to avoid confusion with another drug on the market, a company official said. 
Lunesta will enter the $2 billion market for sleep aids, which is led by Sanofi-Aventis' Ambien. Ambien spent $65 million on U.S. media in 2002, according to Nielsen-Monitor Plus.
Analysts estimate Lunesta could start out with annual sales of $400 million, rising to $750 million or more.
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.